

Roy Gerth van Wijk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6993142/publications.pdf>

Version: 2024-02-01

94
papers

10,641
citations

126907

33
h-index

46799

89
g-index

97
all docs

97
docs citations

97
times ranked

7254
citing authors

#	ARTICLE	IF	CITATIONS
1	One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 454-468.	5.7	39
2	Pros and cons: Should allergen immunotherapy be considered in all patients with allergic asthma?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1070-1072.	5.7	2
3	Proposal of 0.5Âµg of protein/100Âµg of processed food as threshold for voluntary declaration of food allergen traces in processed foodâ€”A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GAÂ²LEN position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1736-1750.	5.7	21
4	Development and validation of combined symptomâ€”medication scores for allergic rhinitis*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2147-2162.	5.7	32
5	Introduction of Heated Cowâ€™s Milk Protein in Challenge-Proven Cowâ€™s Milk Allergic Children: The iAGE Study. <i>Nutrients</i> , 2022, 14, 629.	4.1	6
6	Placebo effects in allergen immunotherapyâ€”An EAACI Task Force Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 629-647.	5.7	31
7	Legends of allergy and immunology: Anthony J. Frewâ€”A true European advocate of allergology and clinical immunology. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1285-1287.	5.7	0
8	The roadmap for allergology in Europe: The European training requirements for the specialty of allergology. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1588-1591.	5.7	4
9	Optimization of a transmural care pathway for allergen immunotherapy to primary care by an integrated personal eHealth environment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2259-2261.	5.7	1
10	Heterogeneity in allergic rhinitis: Explained by inducible mechanistic traits?. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 358-360.	2.9	1
11	Peanut components measured by ISAC: comparison with ImmunoCap and clinical relevance in peanut allergic children. <i>Clinical and Molecular Allergy</i> , 2021, 19, 14.	1.8	6
12	Harmonizing allergy careâ€”integrated care pathways and multidisciplinary approaches. <i>World Allergy Organization Journal</i> , 2021, 14, 100584.	3.5	11
13	Assessment of immediate and non-immediate hypersensitivity contrast reactions by skin tests and provocation tests: A review. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110150.	2.1	9
14	Allergy education and training for physicians. <i>World Allergy Organization Journal</i> , 2021, 14, 100589.	3.5	5
15	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 70-80.e3.	2.9	272
16	Psychological functioning and quality of life in patients with mastocytosis. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 373-378.e2.	1.0	13
17	A meta-analysis of baseline characteristics in trials on mite allergen avoidance in asthmatics: room for improvement. <i>Clinical and Translational Allergy</i> , 2020, 10, 2.	3.2	13
18	Pollen season is reflected on symptom load for grass and birch pollenâ€”induced allergic rhinitis in different geographic areasâ€”An EAACI Task Force Report. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1099-1106.	5.7	34

#	ARTICLE	IF	CITATIONS
19	Describing fluctuating indoor aerosol dust measurements with application to house dust mite allergens. <i>Scientific Reports</i> , 2020, 10, 16897.	3.3	2
20	Pulmonary edema in COVID-19: Explained by bradykinin?. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1454-1455.	2.9	18
21	Effectiveness of the Air Purification Strategies for the Treatment of Allergic Asthma: A Meta-Analysis. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 395-402.	2.1	6
22	IgE cross-reactivity measurement of cashew nut, hazelnut and peanut using a novel IMMULITE inhibition method. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1875-1883.	2.3	4
23	Modulating local airway immune responses to treat allergic asthma: lessons from experimental models and human studies. <i>Seminars in Immunopathology</i> , 2020, 42, 95-110.	6.1	14
24	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK ^{air} App. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1672-1688.	5.7	32
25	Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs. <i>Clinical and Translational Allergy</i> , 2020, 10, 11.	3.2	9
26	Acute systemic reactions to sublingual immunotherapy for house dust mite. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2962-2963.	5.7	5
27	Parental and child factors associated with inhalant and food allergy in a population-based prospective cohort study: the Generation R Study. <i>European Journal of Pediatrics</i> , 2019, 178, 1507-1517.	2.7	12
28	A reintroduction of environmental mite allergen control strategies for asthma treatment and the debate on their effectiveness. <i>Clinical and Experimental Allergy</i> , 2019, 49, 400-409.	2.9	14
29	EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 855-873.	5.7	191
30	2019 ARIA Care pathways for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2087-2102.	5.7	140
31	Toward clinically applicable biomarkers for asthma: An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1835-1851.	5.7	135
32	The roadmap for the Allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper. <i>Clinical and Translational Allergy</i> , 2019, 9, 3.	3.2	19
33	IgE Cross-Reactivity of Cashew Nut Allergens. <i>International Archives of Allergy and Immunology</i> , 2019, 178, 19-32.	2.1	32
34	Low frequency of acetyl salicylic acid hypersensitivity in mastocytosis: The results of a double-blind, placebo-controlled challenge study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2055-2062.	5.7	19
35	EAACI guidelines on allergen immunotherapy: Executive statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 739-743.	5.7	120
36	Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 497-509.e9.	2.9	84

#	ARTICLE	IF	CITATIONS
37	Origin and Processing Methods Slightly Affect Allergenic Characteristics of Cashew Nuts (<i>Anacardium occidentale</i>). Journal of Food Science, 2018, 83, 1153-1164.	3.1	5
38	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (<sc>MACVIA</sc>â€•<sc>ARIA</sc>) â€•<sc>EIP</sc> on <sc>AHA</sc> Twinning Reference Site (<sc>GARD</sc> research demonstration project). Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 77-92.	5.7	54
39	Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 269-283.	5.7	59
40	The roadmap for allergology in Europe: The subspecialty of allergology as â€œstopâ€• on the way to a full specialty. An <sc>EAACI</sc> position statement. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 540-548.	5.7	20
41	Small percentage of anaphylactic reactions treated with epinephrine during food challenges in Dutch children. Annals of Allergy, Asthma and Immunology, 2018, 120, 300-303.	1.0	6
42	Challenges in the implementation of the <sc>EAACI AIT</sc> guidelines: A situational analysis of current provision of allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 827-836.	5.7	44
43	EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 765-798.	5.7	473
44	Current state and future of pediatric allergology in Europe: A road map. Pediatric Allergy and Immunology, 2018, 29, 9-17.	2.6	5
45	Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the <sc>EAACI AIT</sc> Guidelines Project. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 816-826.	5.7	67
46	Challenges in the implementation of <sc>EAACI</sc> guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 64-76.	5.7	72
47	Food Allergy and Asthma: Is There a Link?. Current Treatment Options in Allergy, 2018, 5, 436-444.	2.2	28
48	Positive and negative AIT trials: What makes the difference?. Allergo Journal International, 2018, 27, 167-172.	2.0	10
49	The JAK1/JAK2â€•inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. Clinical and Experimental Allergy, 2018, 48, 1412-1420.	2.9	40
50	Diagnosis of dog allergy: Beware of the dog. Journal of Allergy and Clinical Immunology, 2018, 142, 1058-1059.	2.9	5
51	Maternal psychiatric symptoms during pregnancy and risk of childhood atopic diseases. Clinical and Experimental Allergy, 2017, 47, 509-519.	2.9	31
52	Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future â€• an <sc>EAACI</sc> Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1035-1042.	5.7	85
53	Prediction of cashew nut allergy in sensitized children. Pediatric Allergy and Immunology, 2017, 28, 487-490.	2.6	8
54	Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and metaâ€•analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1597-1631.	5.7	233

#	ARTICLE	IF	CITATIONS
55	Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis – an EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 713-722.	5.7	118
56	Low percentage of clinically relevant pistachio nut and mango co-sensitisation in cashew nut sensitised children. <i>Clinical and Translational Allergy</i> , 2017, 7, 8.	3.2	25
57	Management around invasive procedures in mastocytosis. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 304-309.	1.0	43
58	Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1798.	7.4	185
59	International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. <i>World Allergy Organization Journal</i> , 2017, 10, 14.	3.5	80
60	sIgE Ana o 1, 2 and 3 accurately distinguish tolerant from allergic children sensitized to cashew nuts. <i>Clinical and Experimental Allergy</i> , 2017, 47, 113-120.	2.9	26
61	Allergie van de bovenste en onderste luchtwegen. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2017, 33, 451-458.	0.0	0
62	Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. <i>Clinical and Translational Allergy</i> , 2017, 7, 24.	3.2	49
63	Allergenic food introduction and risk of childhood atopic diseases. <i>PLoS ONE</i> , 2017, 12, e0187999.	2.5	12
64	Multicentre Double-Blind Placebo-Controlled Food Challenge Study in Children Sensitized to Cashew Nut. <i>PLoS ONE</i> , 2016, 11, e0151055.	2.5	32
65	Failure of introduction of cashew nut after a negative oral food challenge test in children. <i>Pediatric Allergy and Immunology</i> , 2016, 27, 654-658.	2.6	8
66	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. <i>Clinical and Translational Allergy</i> , 2016, 6, 41.	3.2	24
67	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	2.9	128
68	No difference in health-related quality of life, after a food challenge with cashew nut in children participating in a clinical trial. <i>Pediatric Allergy and Immunology</i> , 2016, 27, 812-817.	2.6	12
69	Threshold dose distribution and eliciting dose of cashew nut allergy. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 712-714.	1.0	9
70	Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre. <i>European Journal of Internal Medicine</i> , 2016, 30, 25-30.	2.2	29
71	International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoconomics. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 358-368.	2.9	199
72	Perspectives in allergy. <i>Netherlands Journal of Medicine</i> , 2016, 74, 373-375.	0.5	0

#	ARTICLE	IF	CITATIONS
73	The minimal clinically important difference of the control of allergic rhinitis and asthma test (CARAT): cross-cultural validation and relation with pollen counts. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 14107.	2.6	35
74	Measurement and interpretation of skin prick test results. <i>Clinical and Translational Allergy</i> , 2015, 6, 8.	3.2	60
75	Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials?. <i>Current Treatment Options in Allergy</i> , 2015, 2, 1-9.	2.2	11
76	International consensus on allergy immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 556-568.	2.9	427
77	Clinical contraindications to allergen immunotherapy: an EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 897-909.	5.7	177
78	Guidance for the regulatory status of allergen extracts in clinical trials. <i>European Respiratory Journal</i> , 2015, 46, 1223-1225.	6.7	3
79	Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 854-867.	5.7	344
80	Cost-Effectiveness of Subcutaneous Immunotherapy in Allergic Rhinitis Using One or More Allergens - An Analysis Long Overdue. <i>Value in Health</i> , 2014, 17, A597.	0.3	0
81	Sublingual immunotherapy: World Allergy Organization position paper 2013 update. <i>World Allergy Organization Journal</i> , 2014, 7, 6.	3.5	395
82	Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 353-360.e2.	2.9	263
83	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – CA&sup>&sup>2&sup>&sup>LEN – ARIA Position Paper. <i>International Archives of Allergy and Immunology</i> , 2012, 158, 216-231.	2.1	83
84	Occupational rhinitis in bell pepper greenhouse workers: determinants of leaving work and the effects of subsequent allergen avoidance on health-related quality of life. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 903-908.	5.7	29
85	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 466-476.	2.9	1,322
86	Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 8-160.	5.7	3,827
87	Sublingual immunotherapy in children. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 291-298.	3.1	10
88	Pharmacological provocation in nonallergic rhinitis. <i>Clinical Allergy and Immunology</i> , 2007, 19, 283-93.	0.7	0
89	Allergy and Clinical Immunology Services in Europe*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 1191-1196.	5.7	3
90	Freedom to enjoy life - the ultimate goal in allergy management. <i>Clinical and Experimental Allergy Reviews</i> , 2006, 6, 15-19.	0.3	1

#	ARTICLE	IF	CITATIONS
91	Capsaicin treatment of idiopathic rhinitis: The new panacea?. Current Allergy and Asthma Reports, 2006, 6, 132-137.	5.3	8
92	Freedom to enjoy life - the ultimate goal in allergy management. Clinical and Experimental Allergy Reviews, 2006, 6, 15-19.	0.3	1
93	Assessment of quality of life: advantages and pitfalls. Clinical and Experimental Allergy Reviews, 2005, 5, 32-35.	0.3	14
94	Allergy: a global problem. Quality of life. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 1097-1110.	5.7	48